Applied DNA Sciences, Inc. , announced that its COVID-19 collaboration partner, Takis Biotech, a Rome, Italy-based a company focused on the development of cancer vaccines founded by scientists from Merck Research Laboratories, has received approval from the Italy’s Ministry of Health to begin a pre-clinical trial of a COVID-19 vaccine candidate. As announced by Applied DNA on March 2, 2020, the vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA. Applied DNA entered large-scale production of the candidates in March 2020. Takis Biotech anticipates first results of its pre-clinical trial will be available in April 2020.
Click here to read Takis Biotech’s announcement (in English and Italian):
Click here to learn more about Applied DNA’s proprietary linear DNA production capabilities for DNA vaccines:
Visit www.takisbiotech.it for more information.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, diagnostics and pre-clinical nucleic acid-based therapeutic drug candidates.